Leaders in Pharmaceutical Business Intelligence (LPBI) Group

England’s National Cancer Drugs Fund Removes 25 Cancer Indications Involving 16 Separate Drugs from its FY16 Covered List – Announcement by http://www.nmok.net @New Medicine, Inc.

Reporter: Aviva Lev-Ari, PhD, RN at the Request of New Medicine, Inc.

England’s National Cancer Drugs Fund Removes 25 Cancer Indications Involving 16 Separate Drugs from its FY16 Covered List

In January 2015, the CDF removed 25 cancer treatment indications involving 16 separate agents from its annual funding list beginning on March 15, 2015.

In addition the CDF rejected outright another 33 indications involving 19 separate approved anticancer agents.

ABOUT NEW MEDICINE, Inc.

http://pharmaceuticalintelligence.com/joint-ventures/ma-and-exit/leaders-in-pharmaceutical-business-intelligence-and-new-medicine-inc/